De Bellis, Annamaria, Bellastella, Giuseppe, Pernice, Vlenia et al. · The Journal of clinical endocrinology and metabolism · 2021 · DOI
This study looked for specific immune system antibodies that attack the pituitary and hypothalamus—two small brain structures that control hormone production—in people with ME/CFS. Researchers found these antibodies in more than half of ME/CFS patients but none in healthy controls. Patients with these antibodies had lower levels of important hormones (like cortisol and growth hormone), and those with the highest antibody levels had the most severe ME/CFS symptoms.
This study provides evidence that autoimmune mechanisms targeting hormone-regulating brain structures may contribute to ME/CFS symptoms and severity. If these findings are confirmed in larger, diverse populations, it could lead to new diagnostic tests and targeted treatments for ME/CFS patients, particularly those with more disabling forms of the illness.
This study does not prove that these antibodies cause ME/CFS—it shows they are associated with the disease but cannot establish causation from a case-control design. The small sample size (30 patients) and enrollment of only women limits whether these findings apply to all ME/CFS patients. It also does not establish whether identifying these antibodies would change patient treatment or outcomes.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.